• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Tirofiban combined with heparin's effect and safety in the treatment of mild to moderate acute ischemic stroke.
Authors: Qiu T, Li C, Huang L, Xiao H, Deng X, Dai X, Fu S, Wang J, Gong Q, Luo Q, Wang M, He W, Chen M Abstract Tirofiban can be used to treat patients with acute ischemic stroke (AIS), this study was to evaluate the efficacy and safety of tirofiban combined with heparin in the treatment of mild to moderate AIS. A total of 98 patients with mild to moderate AIS randomly were divided into 2 groups within 48 h: the treatment group treated with tirofiban and, and the control group treated with aspirin + clopidogrel. The treatment group was given the same scheme as the control group after the treatment of tirofiban co...
Source: Neurological Research - December 6, 2020 Category: Neurology Tags: Neurol Res Source Type: research

Low density lipoprotein cholesterol values and outcome of stroke patients: influence of previous aspirin therapy.
Conclusion: A worse outcome was seen in stroke patients with normal levels of LDLC, but this finding was restricted to patients not under previous aspirin therapy. PMID: 32024449 [PubMed - as supplied by publisher]
Source: Neurological Research - February 8, 2020 Category: Neurology Tags: Neurol Res Source Type: research

Argatroban plus aspirin versus aspirin in acute ischemic stroke.
CONCLUSION: Argatroban is effective and safe for the treatment of moderate AIS with similar efficacy to high-dose aspirin in the acute phase of AIS, although no additional benefit on short-term outcome was observed. For patients with mild AIS, argatroban may be inferior to high-dose aspirin. PMID: 30052164 [PubMed - as supplied by publisher]
Source: Neurological Research - July 30, 2018 Category: Neurology Tags: Neurol Res Source Type: research

The association between high on-treatment platelet reactivity and early recurrence of ischemic events after minor stroke or TIA.
DISCUSSION: In patients with minor stroke or TIA, the prevalence of HTPR was 22.7%, and HTPR was independently associated with recurrent ischemic events. PMID: 28398139 [PubMed - as supplied by publisher]
Source: Neurological Research - April 13, 2017 Category: Neurology Tags: Neurol Res Source Type: research

Stroke recurrence among 30 days survivors of ischemic stroke in a prospective community-based study.
Authors: Ryglewicz D, Baranska-Gieruszczak M, Czlonkowska A, Lechowicz W, Hier D Abstract A cohort of 209 patients (105 men and 104 women), who survived 30 days after "first ever-in-lifetime ischemic stroke' were followed for one year. Predictors ofsurvival were examined by log-rank test and Cox proportional hazards method. Twenty-four patients had a stroke recurr~nce (11.4%). Thirteen of the patients with recurrent stroke (54%) died because of the sequelae of the second stroke. Stroke recurred in 16% of patients with stoke due to atherosclerosis, in 12.5% of patients with cardioembolic stroke, and in 4.4% of patie...
Source: Neurological Research - November 10, 2016 Category: Neurology Tags: Neurol Res Source Type: research

Combined clopidogrel-aspirin treatment for high risk TIA or minor stroke does not increase cerebral microbleeds.
CONCLUSIONS: For the treatment of high-risk TIA or minor stroke patients, the clopidogrel-aspirin treatment did not increase the number of CMB than Aspirin alone. It appears that the extent of CMB was associated with the extent of existing CMB occurred in previous stroke, which was mostly located in cortical, subcortical zone. PMID: 26391570 [PubMed - in process]
Source: Neurological Research - September 25, 2015 Category: Neurology Tags: Neurol Res Source Type: research

Cilostazol may prevent cardioembolic stroke in patients undergoing antiplatelet therapy.
CONCLUSIONS: Cilostazol may prevent cardioembolic stroke in patients undergoing antiplatelet therapy. This could be a novel strategy for cardioembolic stroke prevention potentially by affecting cardiac remodelling, in contrast to secondary anticoagulant therapy. PMID: 25798683 [PubMed - as supplied by publisher]
Source: Neurological Research - March 24, 2015 Category: Neurology Tags: Neurol Res Source Type: research

Preexisting dual antiplatelet treatment increases the risk of post-thrombolysis intracranial hemorrhage in Chinese stroke patients.
DISCUSSION: The risk of developing sICH is low when thrombolysis is given to patients who are on ASA alone. However, there is potential increased risk of sICH if a patient is on dual AP treatment. PMID: 24861494 [PubMed - in process]
Source: Neurological Research - December 2, 2014 Category: Neurology Tags: Neurol Res Source Type: research

The effect of cilostazol and aspirin pre-treatment against subsequent transient focal cerebral ischemia in rat.
We examined whether 7 days of oral administration of cilostazol protects against subsequent cerebral ischemia, and whether or not the effect of combination therapy with aspirin is more protective. METHODS: We used Sprague-Dawley (SD) rats and assigned them to four groups: vehicle, aspirin, cilostazol, and aspirin plus cilostazol combination therapy. After oral administration of anti-platelets for 7 days, we performed transient middle cerebral artery occlusion (MCAO) for 90 minutes, and examined infarct volume, neurological symptoms, and regional cerebral blood flow (rCBF). Immunostaining of Bax, Bcl-2, TUNEL, 4-HNE, 8-...
Source: Neurological Research - December 2, 2014 Category: Neurology Tags: Neurol Res Source Type: research

Pages: 1  2